Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Todays Updates

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Older Patients on Maintenance Dialysis Underrepresented in RCTs

Older Patients on Maintenance Dialysis Underrepresented in RCTs

Todays Updates

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Older Patients on Maintenance Dialysis Underrepresented in RCTs

Older Patients on Maintenance Dialysis Underrepresented in RCTs

Latest News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Here's some of what is coming soon to NeurologyLive® this week.

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

News All Time

FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.

Long-Term Expanded Access Program Data Support Phase 3 Development of Bexicaserin in Developmental Epileptic Encephalopathies Marco Meglio

New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli

A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

PERC Analysis Highlights Factors Influencing Candidacy for Pediatric Drug-Resistant Epilepsy Surgery Isabella Ciccone, MPH

A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.

Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care Marco Meglio, Sharon Hesterlee, PhD

Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows Louie Pasculli

A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.

Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program Marco Meglio

The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies Marco Meglio

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

Open Label Extension Confirms Cenobamate's Efficacy in Asian Populations Louie Pasculli

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

NeurologyLive® Brain Games: December 7, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome Marco Meglio

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

Recommended News For You

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

Vapers May Be Less Likely to Undergo Lung Cancer Screening

Oral drug combination extends progression-free survival in advanced ER-positive breast cancer

A protein with new anticancer activity has been identified

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

Insurance Claim Denials for Preventive Care More Common in At-Risk Patients

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

Recommended Articles For You

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection? 

Beyond the Biopsy: Decoding Tumor Biology Through the Lens of Radiogenomics 

The Latest Research on Wiskott Aldrich Syndrome  

Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

2.

healthy despite having advanced cancer.

3.

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

4.

Scientists identify dual protein targets to weaken pancreatic cancer defenses

5.

Nasal therapeutic HPV vaccine could prevent cervical cancer

1.

Unlocking Life Expectancy After Subdural Hematoma: A New Hope

2.

The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v

3.

The latest Hematocrit: An Overview of Red Blood Cell Health 

4.

Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education

5.

Advancing Cancer Treatment: Precision Pharmaceutical Care in Oncohematology

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

3.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Navigating the Complexities of Ph Negative ALL - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot